Trade ImmuCell - ICCC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.89 |
| Open | 3.81 |
| 1-Year Change | -13.41% |
| Day's Range | 3.72 - 3.92 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | 3.76 | -0.22 | -5.53% | 3.98 | 3.98 | 3.72 |
| Sep 9, 2024 | 3.89 | -0.11 | -2.75% | 4.00 | 4.03 | 3.83 |
| Sep 6, 2024 | 4.00 | 0.20 | 5.26% | 3.80 | 4.00 | 3.73 |
| Sep 5, 2024 | 3.81 | 0.08 | 2.14% | 3.73 | 3.85 | 3.73 |
| Sep 4, 2024 | 3.79 | 0.13 | 3.55% | 3.66 | 3.80 | 3.66 |
| Sep 3, 2024 | 3.74 | 0.03 | 0.81% | 3.71 | 3.76 | 3.71 |
| Aug 30, 2024 | 3.72 | -0.08 | -2.11% | 3.80 | 3.86 | 3.68 |
| Aug 29, 2024 | 3.78 | 0.01 | 0.27% | 3.77 | 3.79 | 3.72 |
| Aug 28, 2024 | 3.76 | -0.26 | -6.47% | 4.02 | 4.02 | 3.51 |
| Aug 27, 2024 | 4.10 | 0.46 | 12.64% | 3.64 | 4.10 | 3.64 |
| Aug 26, 2024 | 3.64 | 0.00 | 0.00% | 3.64 | 3.71 | 3.64 |
| Aug 23, 2024 | 3.67 | 0.15 | 4.26% | 3.52 | 3.71 | 3.49 |
| Aug 22, 2024 | 3.53 | -0.12 | -3.29% | 3.65 | 3.66 | 3.51 |
| Aug 21, 2024 | 3.60 | -0.04 | -1.10% | 3.64 | 3.71 | 3.51 |
| Aug 20, 2024 | 3.64 | -0.05 | -1.36% | 3.69 | 3.69 | 3.57 |
| Aug 19, 2024 | 3.64 | 0.13 | 3.70% | 3.51 | 3.64 | 3.51 |
| Aug 16, 2024 | 3.59 | -0.01 | -0.28% | 3.60 | 3.69 | 3.59 |
| Aug 15, 2024 | 3.59 | 0.10 | 2.87% | 3.49 | 3.64 | 3.41 |
| Aug 14, 2024 | 3.49 | -0.06 | -1.69% | 3.55 | 3.56 | 3.47 |
| Aug 13, 2024 | 3.74 | 0.03 | 0.81% | 3.71 | 3.74 | 3.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ImmuCell Company profile
About ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
Financial summary
BRIEF: For the nine months ended 30 September 2021, ImmuCell Corporation revenues increased 19% to $13.8M. Net loss decreased 87% to $152K. Revenues reflect First Defense® product line segment increase of 44% to $9.5M, Other animal health segment increase of 83% to $186K, United States segment increase of 18% to $12.2M, Others segment increase of 28% to $1.6M.
Equity composition
Common Stock $.10 Par, 12/10, 8M auth., 3,261,148 issd., less 287,496 shs. in Treas. @ $635K. Insiders own 26.70%. PO 5/87, 966,000 Units (100 Common + 5 Warrants) @ $7/Unit by Stuart James. 7/90, 1-for-100 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
56 Evergreen Drive
PORTLAND
MAINE 04103
US
News
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com